Have you seen the talent Matinas has attracted? That actually came to them? It’s worth looking into.
As said in the last post, you may be better served thinking of this as the evolving statin market. Once 4S established the efficacy of HMG-CoA reductase inhibitors to reduce ASCVD, numerous other HMG-CoA reductase inhibitors came out that did not have outcomes studies, but docs prescribed them anyway over the older versions. Why? They were better at doing what they were designed to: lower lipids and inflammation. Now, there are rTG and other forms of EPA our there, and they are better than EE forms like Vascepa. There’s just no denying it. It’s a significant headwind for AMRN bulls.
On MAT-9001 we went patent diving and found some very interesting things. It’s essentially 85% free fatty acid EPA and around 10% FFA-DPA. Think of an Epanova analogue to Vacsepa, with some DPA to differentiate IP. If Amarin makes it, they will run their hypertrig study and get on the market fast. Then it’s up to docs, who may very well choose it over Vacsepa.
But Amarin is not likely to make it. Highly probable they will be delisted before end 2022, or cease to be a going concern altogether by then.
-MRC
News 
Market Data 
Discover 
AI
